Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,772.00 | 1.00 | -0.01% |
| CAC 40 | 7,662.59 | 3.32 | -0.04% |
| DAX 40 | 23,673.29 | 236.32 | -0.99% |
| Dow JONES (US) | 44,575.47 | 480.70 | 1.09% |
| FTSE 100 | 8,785.33 | 24.37 | 0.28% |
| HKSE | 24,072.28 | 211.87 | -0.87% |
| NASDAQ | 20,240.17 | 129.57 | -0.64% |
| Nikkei 225 | 39,986.33 | 501.06 | -1.24% |
| NZX 50 Index | 12,734.53 | 131.71 | 1.05% |
| S&P 500 | 6,206.32 | 1.37 | 0.02% |
| S&P/ASX 200 | 8,541.10 | 1.20 | -0.01% |
| SSE Composite Index | 3,444.43 | 20.20 | 0.59% |